• Enzalutamide Improves Survival in Men With Metastatic Prostate Cancer

    1 month ago - By Medscape

    Enzalutamide improves 5-year survival in men with chemotherapy-naive metastatic castration-resistant prostate cancer, but increases the risk of fatal adverse events, according to final results from the PREVAIL trial.
    Reuters Health Information
    Read more ...